Therapeutic efficacy of TMS-19-Q·GC tablet on respiratory tract infection

Seiichi Aonuma, Kikuo Onuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno, Kosaku Nagai

    Research output: Contribution to journalArticlepeer-review


    A total of five patients with respiratory tract infections, one each patient having pneumonia, acute bronchitis, acute tonsillitis and two having pharyngitis, were treated with oral administration of TMS-19-Q·GC at a daily dose of 600mg for five to 23 days. Clinical response was good in three of the patients and fair in the remaining two patients. No adverse symptom and sign was noted during the administration of the drug.

    Original languageEnglish
    Pages (from-to)245-247
    Number of pages3
    Publication statusPublished - 1984 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'Therapeutic efficacy of TMS-19-Q·GC tablet on respiratory tract infection'. Together they form a unique fingerprint.

    Cite this